Drug intelligence / Profile preview

BCM332

Development stage: Unknown
Lead developer: Shanghai Bocimed Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

BCM332 is a small molecule, highly selective inhibitor of the voltage-gated sodium channel Nav1.6 (SCN8A), developed by Shanghai Bozhi Yanshen Pharmaceutical Technology Co., Ltd. It is primarily indicated for the treatment of epilepsy, specifically focal seizures. By selectively blocking Nav1.6, which is a major mediator of neuronal firing in the central nervous system, BCM332 aims to provide potent anti-seizure activity with an improved safety profile compared to non-selective sodium channel blockers. The drug is currently undergoing Phase II clinical evaluation in China.

Targets

SCN8A (NaV1.6)

Beyond the preview

Go deeper on BCM332.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BCM332.

Explore the full profile